Characterizing In Vivo Pharmacodynamics of Carbapenems against Acinetobacter baumannii in a Murine Thigh Infection Model To Support Breakpoint Determinations

被引：17

作者：

MacVane, Shawn H. ^{[1
]}

Crandon, Jared L. ^{[1
]}

Nicolau, David P. ^{[1
,2
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06115 USA

[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 01期

关键词：

PSEUDOMONAS-AERUGINOSA; RESISTANCE; PNEUMONIAE; MEROPENEM;

D O I：

10.1128/AAC.02029-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Pharmacodynamic profiling data of carbapenems for Acinetobacter spp. are sparse. This study aimed to determine the pharmacodynamic targets of carbapenems for Acinetobacter baumannii based on a range of percentages of the dosing interval in which free drug concentrations remained above the MIC (fT>MIC) in the neutropenic murine thigh infection model. fT>MIC values of 23.7%, 32.8%, and 47.5% resulted in stasis, 1-log reductions, and 2-log reductions in bacterial density after 24 h, respectively. The pharmacodynamic targets of carbapenems for A. baumannii demonstrated in vivo are similar to those of other Gram-negative bacteria.

引用

页码：599 / 601

页数：3

共 13 条

[1] In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].

Andes, D ;

Craig, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379

[2]

Clinical Laboratory and Standards Institute, 2013, CLSI PUBL

[3] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10

[4]

Craig WA, 1993, 35 INT C ANT AG CHEM

[5] Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers [J].

Crandon, Jared L. ;

Nicolau, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) :3299-3306

[6] Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model [J].

DeRyke, C. Andrew ;

Banevicius, Mary Anne ;

Fan, Hong Wei ;

Nicolau, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1481-1486

[7] Prevention of resistance: A goal for dose selection for antimicrobial agents [J].

Drusano, GL .

CLINICAL INFECTIOUS DISEASES, 2003, 36 :S42-S50

[8] Treatment of Acinetobacter Infections [J].

Fishbain, Joel ;

Peleg, Anton Y. .

CLINICAL INFECTIOUS DISEASES, 2010, 51 (01) :79-84

[9] In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures [J].

Kim, Aryun ;

Banevicius, Mary Anne ;

Nicolau, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2497-2502

[10] Acinetobacter baumannii:: Epidemiology, antimicrobial resistance, and treatment options [J].

Maragakis, Lisa L. ;

Perl, Trish M. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (08) :1254-1263

← 1 2 →